作者:Steven V. Ley、Miles N. Tackett、Matthew L. Maddess、James C. Anderson、Paul E. Brennan、Michael W. Cappi、Jag P. Heer、Céline Helgen、Masakuni Kori、Cyrille Kouklovsky、Stephen P. Marsden、Joanne Norman、David P. Osborn、María Á. Palomero、John B. J. Pavey、Catherine Pinel、Lesley A. Robinson、Jürgen Schnaubelt、James S. Scott、Christopher D. Spilling、Hidenori Watanabe、Kieron E. Wesson、Michael C. Willis
DOI:10.1002/chem.200801656
日期:2009.3.9
Rapamycin (1) is a macrocyclic natural product, established as a potent immunosuppressant and currently of interest to the scientific community as the framework for a series of novel anticancer drugs. Extensive studies have culminated in a new convergent totalsynthesis of 1, which features a number of group‐derived methodologies and an unusual catechol‐templating strategy for the construction of the